Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of July 2022).

In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.

Program (Target)	Potential Indication(s)	First-in-Human (Phase 1)	Proof-of-Concept (Phase 2)	Pivotal (Phase 3)	Major Market Rights
MGC018 (B7-H3)	mCRPC, NSCLC, SCCHN, Melanoma	placeholder
	Multiple Solid Tumors (+lorigerlimab)	placeholder
Lorigerlimab (PD-1 × CTLA-4)	MSS CRC, NSCLC, mCRPC, Melanoma	placeholder
Tebotelimab (PD-1 × LAG-3)	Solid Tumors & Heme Malignancies	placeholder					Greater China
IMGC936 (ADAM9)	Multiple Solid Tumors	placeholder				50/50
MGD024 (CD123 × CD3)	CD123+ Heme Malignancies	placeholder Plan to initiate in mid-2022a

Oncology

MGC018 (B7-H3)

mCRPC, NSCLC, SCCHN, Melanoma

Phase 1	Phase 2	Phase3
placeholder

Multiple Solid Tumors (+lorigerlimab)

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Lorigerlimab
(PD-1 × CTLA-4)

MSS CRC, NSCLC, mCRPC, Melanoma

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Tebotelimab
(PD-1 × LAG-3)

Solid Tumors & Heme Malignancies

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

Greater China

IMGC936
(ADAM9)

Multiple Solid Tumors

Phase 1	Phase 2	Phase3
placeholder

Major Market Rights:

50/50

MGD024
(CD123 × CD3)

CD123+ Heme Malignancies

Phase 1	Phase 2	Phase3
placeholder Plan to initiate in mid-2022a

Major Market Rights: